Inhibitory effect of black tea pigments, theaflavin‑3/3'-gallate against cisplatin-resistant ovarian cancer cells by inducing apoptosis and G1 cell cycle arrest

Pan,Haibo; Wang,Fang; Rankin,Gary O.; Rojanasakul,Yon; Tu,Youying; Chen,Yi Charlie

doi:10.3892/ijo.2017.4145

Inhibitory effect of black tea pigments, theaflavin‑3/3'-gallate against cisplatin-resistant ovarian cancer cells by inducing apoptosis and G1 cell cycle arrest

Authors:
- Haibo Pan
- Fang Wang
- Gary O. Rankin
- Yon Rojanasakul
- Youying Tu
- Yi Charlie Chen
View Affiliations

Affiliations: Department of Tea Science, Zhejiang University, Hangzhou, Zhejiang, P.R. China, Department of Tea Science, Wuyi University, Wuyishan, Fujian, P.R. China, Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA, Department of Pharmaceutical Sciences, West Virginia University, Morgantown, WV, USA, College of Science, Technology and Mathematics, Alderson Broaddus University, Philippi, WV, USA
Published online on: October 3, 2017 https://doi.org/10.3892/ijo.2017.4145
Pages: 1508-1520

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adverse side effects and acquired resistance to conventional chemotherapy based on platinum drive the exploration of other selective anticancer drugs. Theaflavin‑3-gallate (TF2a) and theaflavin‑3'-gallate (TF2b), theaflavin monomers in black tea, exhibited a potent growth inhibitory effect on cisplatin-resistant ovarian cancer A2780/CP70 cells and were less cytotoxic to normal ovarian IOSE-364 cell line. Flow cytometry analysis and western blotting indicated that TF2a and TF2b induced apoptosis and G1 cell cycle arrest in ovarian cancer A2780/CP70 cells. Hoechst 33342 staining was used to confirm the apoptotic effect. Downregulation of CDK2 and CDK4 for TF2a and CDK2 and cyclin E1 for TF2b led to the accumulation of cells in G1 phase. TF2a and TF2b induced apoptosis and G1 through p53-dependent pathways. TF2a and TF2b induced DNA damage through ATM/Chk/p53 pathway. TF2a and TF2b also induced inhibition of A2780/CP70 cells through Akt and MAPK pathways. The results of this study implied that TF2a and TF2b might help prevent and treat platinum-resistant ovarian cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Ali AY, Farrand L, Kim JY, Byun S, Suh JY, Lee HJ and Tsang BK: Molecular determinants of ovarian cancer chemoresistance: New insights into an old conundrum. Ann NY Acad Sci. 1271:58–67. 2012. View Article : Google Scholar : PubMed/NCBI
3	Limtrakul P, Pitchakarn P and Suzuki S: Kuguacin J, a Triterpenoid from Momordica charantia Linn: A Comprehensive Review of Anticarcinogenic Properties. INTECH Open Access Publisher; View Article : Google Scholar : 2013
4	Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S and Galaal K: Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. Feb;28(2): CD008765 View Article : Google Scholar : 2013.
5	Wang V, Li C, Lin M, Welch W, Bell D, Wong YF, Berkowitz R, Mok SC and Bandera CA: Ovarian cancer is a heterogeneous disease. Cancer Genet Cytogenet. 161:170–173. 2005. View Article : Google Scholar : PubMed/NCBI
6	Cragg DJ, Kingston GM and Newman DG: Anticancer Agents from Natural Products. CRC Press; 2011, View Article : Google Scholar
7	Butler MS, Robertson AA and Cooper MA: Natural product and natural product derived drugs in clinical trials. Nat Prod Rep. 31:1612–1661. 2014. View Article : Google Scholar : PubMed/NCBI
8	Newman DJ and Cragg GM: Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 79:629–661. 2016. View Article : Google Scholar : PubMed/NCBI
9	Goldbohm RA, Hertog MG, Brants HA, van Poppel G and van den Brandt PA: Consumption of black tea and cancer risk: A prospective cohort study. J Natl Cancer Inst. 88:93–100. 1996. View Article : Google Scholar : PubMed/NCBI
10	Cassidy A, Huang T, Rice MS, Rimm EB and Tworoger SS: Intake of dietary flavonoids and risk of epithelial ovarian cancer. Am J Clin Nutr. 100:1344–1351. 2014. View Article : Google Scholar : PubMed/NCBI
11	Finger A: In vitro studies on the effect of polyphenol oxidase and peroxidase on the formation of polyphenolic black tea constituents. J Sci Food Agric. 66:293–305. 1994. View Article : Google Scholar
12	Yang GY, Liu Z, Seril DN, Liao J, Ding W, Kim S, Bondoc F and Yang CS: Black tea constituents, theaflavins, inhibit 4- (methylnitrosamino)-1- (3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in A/J mice. Carcinogenesis. 18:2361–2365. 1997. View Article : Google Scholar
13	Lu J, Ho C-T, Ghai G and Chen KY: Differential effects of theaflavin monogallates on cell growth, apoptosis, and Cox-2 gene expression in cancerous versus normal cells. Cancer Res. 60:6465–6471. 2000.PubMed/NCBI
14	Hibasami H, Komiya T, Achiwa Y, Ohnishi K, Kojima T, Nakanishi K, Sugimoto Y, Hasegawa M, Akatsuka R and Hara Y: Black tea theaflavins induce programmed cell death in cultured human stomach cancer cells. Int J Mol Med. 1:725–727. 1998.PubMed/NCBI
15	Lahiry L, Saha B, Chakraborty J, Adhikary A, Mohanty S, Hossain DM, Banerjee S, Das K, Sa G and Das T: Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells. Carcinogenesis. 31:259–268. 2010. View Article : Google Scholar
16	Tu Y, Kim E, Gao Y, Rankin GO, Li B and Chen YC: Theaflavin-3, 3′-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells. Int J Oncol. 48:2657–2665. 2016.PubMed/NCBI
17	Gao Y, Rankin GO, Tu Y and Chen YC: Theaflavin-3, 3′-digallate decreases human ovarian carcinoma OVCAR-3 cell-induced angiogenesis via Akt and Notch-1 pathways, not via MAPK pathways. Int J Oncol. 48:281–292. 2016. View Article : Google Scholar
18	Gao Y, Rankin GO, Tu Y and Chen YC: Inhibitory Effects of the Four Main Theaflavin Derivatives Found in Black Tea on Ovarian Cancer Cells. Anticancer Res. 36:643–651. 2016.PubMed/NCBI
19	Xu Y, Jin Y, Wu Y and Tu Y: Isolation and purification of four individual theaflavins using semi-preparative high performance liquid chromatography. J Liq Chromatogr Relat Technol. 33:1791–1801. 2010. View Article : Google Scholar
20	Levine AJ: p53 the cellular gatekeeper for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
21	Lakin ND and Jackson SP: Regulation of p53 in response to DNA damage. Oncogene. 18:7644–7655. 1999. View Article : Google Scholar
22	Burma S, Chen BP, Murphy M, Kurimasa A and Chen DJ: ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem. 276:42462–42467. 2001. View Article : Google Scholar : PubMed/NCBI
23	Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C and Abraham RT: A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 13:152–157. 1999. View Article : Google Scholar : PubMed/NCBI
24	Gottlieb TM, Leal JFM, Seger R, Taya Y and Oren M: Cross-talk between Akt, p53 and Mdm2: Possible implications for the regulation of apoptosis. Oncogene. 21:1299–1303. 2002. View Article : Google Scholar : PubMed/NCBI
25	Franke TF, Kaplan DR and Cantley LC: PI3K: Downstream AKTion blocks apoptosis. Cell. 88:435–437. 1997. View Article : Google Scholar : PubMed/NCBI
26	Franke TF, Yang S-I, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR and Tsichlis PN: The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF- activated phosphatidylinositol 3-kinase. Cell. 81:727–736. 1995. View Article : Google Scholar : PubMed/NCBI
27	Diehl JA, Cheng M, Roussel MF and Sherr CJ: Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12:3499–3511. 1998. View Article : Google Scholar : PubMed/NCBI
28	Wu GS: The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther. 3:156–161. 2004. View Article : Google Scholar : PubMed/NCBI
29	Blagosklonny MV: Overcoming limitations of natural anticancer drugs by combining with artificial agents. Trends Pharmacol Sci. 26:77–81. 2005. View Article : Google Scholar : PubMed/NCBI
30	Wong RS: Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011. View Article : Google Scholar : PubMed/NCBI
31	Hassan M, Watari H, AbuAlmaaty A, Ohba Y and Sakuragi N: Apoptosis and molecular targeting therapy in cancer. BioMed Res Int. 2014:1508452014. View Article : Google Scholar : PubMed/NCBI
32	McIlwain DR, Berger T and Mak TW: Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 7:72015. View Article : Google Scholar
33	Knaapen M, De Bie M, Muhring J and Kockx M: Cleaved PARP as a marker for apoptosis in tissue sections. Promega Notes. 72:71999.
34	Los M, Mozoluk M, Ferrari D, Stepczynska A, Stroh C, Renz A, Herceg Z, Wang ZQ and Schulze-Osthoff K: Activation and caspase-mediated inhibition of PARP: A molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol Biol Cell. 13:978–988. 2002. View Article : Google Scholar : PubMed/NCBI
35	Morales J, Li L, Fattah FJ, Dong Y, Bey EA, Patel M, Gao J and Boothman DA: Review of poly (ADP-Ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr. 24:15–28. 2014. View Article : Google Scholar : PubMed/NCBI
36	Chow A: Cell cycle control by oncogenes and tumor suppressors: Driving the transformation of normal cells into cancerous cells. Nature Education. 3:72010.
37	Sherr CJ and Bartek J: Cell cycle-targeted cancer therapies. Annu Rev Cancer Biol. 1:41–57. 2017. View Article : Google Scholar
38	Zhang G, Miura Y and Yagasaki K: Induction of apoptosis and cell cycle arrest in cancer cells by in vivo metabolites of teas. Nutr Cancer. 38:265–273. 2000. View Article : Google Scholar
39	Prasad S, Kaur J, Roy P, Kalra N and Shukla Y: Theaflavins induce G2/M arrest by modulating expression of p21^waf1/cip1, cdc25C and cyclin B in human prostate carcinoma PC-3 cells. Life Sci. 81:1323–1331. 2007. View Article : Google Scholar : PubMed/NCBI
40	Kawabe T: G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther. 3:513–519. 2004.PubMed/NCBI
41	Waldman T, Kinzler KW and Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:5187–5190. 1995.PubMed/NCBI
42	Yu W, Park S-K, Jia L, Tiwary R, Scott WW, Li J, Wang P, Simmons-Menchaca M, Sanders BG and Kline K: RRR-γ-tocopherol induces human breast cancer cells to undergo apoptosis via death receptor 5 (DR5)-mediated apoptotic signaling. Cancer Lett. 259:165–176. 2008. View Article : Google Scholar
43	Ozaki T and Nakagawara A: Role of p53 in cell death and human cancers. Cancers (Basel). 3:994–1013. 2011. View Article : Google Scholar
44	Khoo KH, Verma CS and Lane DP: Drugging the p53 pathway: Understanding the route to clinical efficacy. Nat Rev Drug Discov. 13:217–236. 2014. View Article : Google Scholar : PubMed/NCBI
45	Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtĕsek B and Kaye SB: Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer. 55:678–684. 1993. View Article : Google Scholar : PubMed/NCBI
46	Lahiry L, Saha B, Chakraborty J, Bhattacharyya S, Chattopadhyay S, Banerjee S, Choudhuri T, Mandal D, Bhattacharyya A, Sa G, et al: Contribution of p53-mediated Bax transactivation in theaflavin- induced mammary epithelial carcinoma cell apoptosis. Apoptosis. 13:771–781. 2008. View Article : Google Scholar : PubMed/NCBI
47	Kalra N, Seth K, Prasad S, Singh M, Pant AB and Shukla Y: Theaflavins induced apoptosis of LNCaP cells is mediated through induction of p53 down-regulation of NF-kappa B and mitogen-activated protein kinases pathways. Life Sci. 80:2137–2146. 2007. View Article : Google Scholar : PubMed/NCBI
48	Meek DW: The p53 response to DNA damage. DNA Repair (Amst). 3:1049–1056. 2004. View Article : Google Scholar
49	Lee JH and Paull TT: Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene. 26:7741–7748. 2007. View Article : Google Scholar : PubMed/NCBI
50	Zhao H and Piwnica-Worms H: ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol. 21:4129–4139. 2001. View Article : Google Scholar : PubMed/NCBI
51	Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K and Elledge SJ: Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA. 97:10389–10394. 2000. View Article : Google Scholar : PubMed/NCBI
52	Melchionna R, Chen X-B, Blasina A and McGowan CH: Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nat Cell Biol. 2:762–765. 2000. View Article : Google Scholar : PubMed/NCBI
53	Yuan J, Adamski R and Chen J: Focus on histone variant H2AX: To be or not to be. FEBS Lett. 584:3717–3724. 2010. View Article : Google Scholar : PubMed/NCBI
54	Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM: DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 273:5858–5868. 1998. View Article : Google Scholar : PubMed/NCBI
55	Shieh S-Y, Ikeda M, Taya Y and Prives C: DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 91:325–334. 1997. View Article : Google Scholar : PubMed/NCBI
56	Sahu RP, Batra S and Srivastava SK: Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br J Cancer. 100:1425–1433. 2009. View Article : Google Scholar : PubMed/NCBI
57	Lee H, Kim Y, Jeong JH, Ryu J-H and Kim W-Y: ATM/CHK/p53 pathway dependent chemopreventive and therapeutic activity on lung cancer by pterostilbene. PloS One. 11:e01623352016. View Article : Google Scholar : PubMed/NCBI
58	Altomare DA and Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464. 2005. View Article : Google Scholar : PubMed/NCBI
59	Crowell JA, Steele VE and Fay JR: Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther. 6:2139–2148. 2007. View Article : Google Scholar : PubMed/NCBI
60	Mabuchi S, Kuroda H, Takahashi R and Sasano T: The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 137:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
61	Abraham AG and O'Neill E: PI3K/Akt-mediated regulation of p53 in cancer. Biochem Soc Trans. 42:798–803. 2014. View Article : Google Scholar : PubMed/NCBI
62	Kim CW, Lu JN, Go S-I, Jung JH, Yi SM, Jeong JH, Hah YS, Han MS, Park JW, Lee WS, et al: p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax. Int J Oncol. 43:1495–1502. 2013. View Article : Google Scholar : PubMed/NCBI
63	Koul HK, Pal M and Koul S: Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer. 4:342–359. 2013. View Article : Google Scholar : PubMed/NCBI
64	Cheng T-L, Symons M and Jou T-S: Regulation of anoikis by Cdc42 and Rac1. Exp Cell Res. 295:497–511. 2004. View Article : Google Scholar : PubMed/NCBI
65	Hong B, Li H, Zhang M, Xu J, Lu Y, Zheng Y, Qian J, Chang JT, Yang J and Yi Q: p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. Int J Cancer. 136:34–43. 2015. View Article : Google Scholar
66	Kohno M and Pouyssegur J: Targeting the ERK signaling pathway in cancer therapy. Ann Med. 38:200–211. 2006. View Article : Google Scholar : PubMed/NCBI
67	Dong Z, Ma W, Huang C and Yang CS: Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (−)-epigallocatechin gallate, and theaflavins. Cancer Res. 57:4414–4419. 1997.PubMed/NCBI
68	Vivas-Mejia P, Benito JM, Fernandez A, Han H-D, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, et al: JNK-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res. 16:184–194. 2010. View Article : Google Scholar
69	Kitanaka C, Sato A and Okada M: JNK signaling in the control of the tumor-initiating capacity associated with cancer stem cells. Genes Cancer. 4:388–396. 2013. View Article : Google Scholar : PubMed/NCBI